Abbott Laboratories (NYSE:ABT) – Stock analysts at William Blair increased their FY2018 earnings per share estimates for shares of Abbott Laboratories in a report released on Thursday, April 19th. William Blair analyst M. Kaczor now anticipates that the healthcare product maker will earn $2.87 per share for the year, up from their previous forecast of $2.85. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Abbott Laboratories’ Q1 2019 earnings at $0.66 EPS and FY2019 earnings at $3.20 EPS.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.58 by $0.01. Abbott Laboratories had a return on equity of 14.53% and a net margin of 1.67%. The firm had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $7.28 billion. During the same period last year, the firm posted $0.48 EPS. The business’s revenue was up 16.7% on a year-over-year basis.
Several other equities research analysts have also recently commented on ABT. Morgan Stanley raised Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 target price for the company in a research note on Tuesday, January 2nd. JPMorgan Chase raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 target price for the company in a research note on Tuesday, January 2nd. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research note on Tuesday, January 2nd. Evercore ISI assumed coverage on Abbott Laboratories in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $64.00 price objective for the company. Finally, Barclays reaffirmed a “buy” rating and set a $66.00 price objective on shares of Abbott Laboratories in a research note on Monday, January 8th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $66.83.
NYSE ABT opened at $59.88 on Friday. The firm has a market capitalization of $103,941.80, a PE ratio of 23.95, a PEG ratio of 1.76 and a beta of 1.50. Abbott Laboratories has a 52 week low of $42.88 and a 52 week high of $64.60. The company has a quick ratio of 1.86, a current ratio of 2.26 and a debt-to-equity ratio of 0.87.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 annualized dividend and a yield of 1.87%. Abbott Laboratories’s dividend payout ratio is presently 44.80%.
In other news, Director Daniel J. Starks purchased 40,037 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were bought at an average cost of $60.67 per share, for a total transaction of $2,429,044.79. Following the completion of the acquisition, the director now directly owns 6,943,348 shares in the company, valued at approximately $421,252,923.16. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Stephen R. Fussell sold 13,313 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total value of $836,588.92. Following the completion of the sale, the executive vice president now owns 152,343 shares in the company, valued at $9,573,234.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,261 shares of company stock worth $7,559,987. Corporate insiders own 0.74% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Keel Point LLC increased its position in shares of Abbott Laboratories by 2.2% in the second quarter. Keel Point LLC now owns 13,580 shares of the healthcare product maker’s stock valued at $660,000 after acquiring an additional 294 shares during the last quarter. Simmons Bank increased its position in shares of Abbott Laboratories by 1.5% in the second quarter. Simmons Bank now owns 23,978 shares of the healthcare product maker’s stock valued at $1,166,000 after acquiring an additional 343 shares during the last quarter. Hutner Capital Management Inc. increased its position in shares of Abbott Laboratories by 1.0% in the second quarter. Hutner Capital Management Inc. now owns 42,298 shares of the healthcare product maker’s stock valued at $2,056,000 after acquiring an additional 411 shares during the last quarter. South Texas Money Management Ltd. increased its position in shares of Abbott Laboratories by 5.7% in the second quarter. South Texas Money Management Ltd. now owns 8,195 shares of the healthcare product maker’s stock valued at $398,000 after acquiring an additional 444 shares during the last quarter. Finally, National Asset Management Inc. increased its position in Abbott Laboratories by 2.4% during the second quarter. National Asset Management Inc. now owns 20,413 shares of the healthcare product maker’s stock worth $993,000 after buying an additional 473 shares during the last quarter. Institutional investors own 72.34% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “FY2018 EPS Estimates for Abbott Laboratories Increased by William Blair (ABT)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/20/fy2018-eps-estimates-for-abbott-laboratories-increased-by-william-blair-abt.html.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.